US20190365950A1 - Tissue scaffolds - Google Patents
Tissue scaffolds Download PDFInfo
- Publication number
- US20190365950A1 US20190365950A1 US16/544,433 US201916544433A US2019365950A1 US 20190365950 A1 US20190365950 A1 US 20190365950A1 US 201916544433 A US201916544433 A US 201916544433A US 2019365950 A1 US2019365950 A1 US 2019365950A1
- Authority
- US
- United States
- Prior art keywords
- treatment device
- wound treatment
- tissue
- tissue matrix
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Definitions
- Reduced pressure, or vacuum-assisted, therapies can be effective for improving wound healing due to a variety of different causes and at a number of different anatomical locations.
- reduced pressure therapies include a porous material that is placed at a wound site, which aids in the distribution of the reduced pressure.
- Typical porous materials are sized to fit the wound, and may be periodically replaced with smaller pieces of the porous material as the wound begins to heal and becomes smaller.
- a membrane or drape is placed over the porous material to provide an airtight seal at the wound area, and a negative pressure is applied to the porous material to provide a reduced pressure at the wound site.
- FIG. 1 illustrates a wound treatment device, which provides reduced pressure therapy, according to certain exemplary embodiments.
- FIG. 2 illustrates a method of treating a cartilage defect using a tissue scaffold, according to certain embodiments.
- FIGS. 3A-3D are graphs showing the strut spacing for tissue scaffolds, as described in Example 1.
- FIG. 4 is a graph showing the permeability versus composition for tissue scaffolds, as described in Example 2.
- FIG. 5 is a graph showing the strut spacing for a tissue scaffold produced according to certain exemplary embodiments, as described in Example 3.
- FIGS. 6A-6B are photomicrographs of chondrocytes cultured on tissue scaffolds, as described in Example 4.
- FIGS. 7A-7B are photomicrographs of chondrocytes cultured on tissue scaffolds, as described in Example 4.
- the present disclosure pertains to a method of processing an acelluar tissue matrix for preparing a tissue scaffold.
- the tissue scaffold of the present disclosure may be used as part of a wound treatment device that provides reduced pressure therapy.
- the physical properties of certain tissue scaffolds such as porosity, strut density, and permeability, may be controlled or altered by adjusting the concentrations, components, and temperatures at which the scaffolds are produced.
- acellular tissue matrix refers generally to any tissue matrix that is substantially free of cells and other antigenic material.
- acellular tissue matrices derived from human or xenogenic sources may be used to produce the scaffolds.
- Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, nerve, or other collagen containing-organ or tissue may be used to create an acellular matrices to produce tissues scaffolds within the scope of the present disclosure.
- reduced pressure generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure of tissue at the tissue site. Reduced pressure may initially generate fluid flow in the area of the tissue site and/or a fluid conduit in communication with the tissue site, for example, as shown in FIG. 1 . As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. In some embodiments, small amounts of gas can be introduced at intervals to facilitate fluid movement if required. Unless otherwise indicated, values of pressure stated herein are gage pressures.
- fluid generally refers to a gas or liquid, but may also include any other flowable material, including but not limited to gels, colloids, and foams.
- tissue scaffolds can be used in a wide array of applications.
- Certain exemplary applications include, but are not limited to, absorptive dressing, dermal regeneration (for example, for treatments of all types of ulcers and burns), nerve regeneration, cartilage regeneration, connective tissue regeneration or repair (for example, tendon/ligament sleeve), bone regeneration, periodontal applications, wound/foam lining, integrated bandage dressing, substrate/base for skin grafts, vascular regeneration, cosmetic surgery, cosmetic injectable gel, metal and/or polymer implant coating (for example, to increase implant integration and biocompatibility), and replacement of lost tissue (e.g., after trauma, breast reduction, mastectomy, lumpectomy, parotidectomy, or excision of tumors).
- the flexible sheet 160 will include a flexible polymeric material.
- any suitable polymeric material can be selected.
- the material does not cause significant irritation, immune response, or heightened risk of infection.
- the specific material generally should be of sufficient thickness and impermeability to allow reduced pressure therapy at a wound site under the sheet 160 .
- the device 100 will include an adhesive.
- adhesive will be understood to refer to any substance that causes the surfaces of two objects to be attached to one another.
- suitable adhesives can include a variety of different cements, glues, resins, or other materials that can facilitate attachment of the flexible sheet 160 to tissue.
- the adhesive can include a pressure-sensitive acrylic adhesive.
- the adhesives can be applied directly to the structures to be joined, or the adhesives may be applied on tape, or with other supporting substrate materials.
- the adhesive can be applied to a surface of the flexible sheet 160 to attach the sheet to skin or other tissue. In some embodiments, the adhesive will be applied to the surface of the sheet and packaged and/or distributed with the sheet 160 . In some embodiments, the adhesive is applied to a surface of the sheet 160 and covered by a non-adhesive material that can be removed to expose the adhesive for use. In certain embodiments, the adhesive can be supplied as a separate component (e.g., in a container or on a tape) that is applied to the sheet 160 to attach the sheet 160 to tissue. In some embodiments, the adhesive can be applied to a patient's skin or other tissue, and the sheet can be applied to the adhesive.
- tissue scaffold 180 can include a variety of suitable materials. For example, a number of different tissue scaffolds will be compatible for use with the above-noted V.A.C.® treatment systems.
- the tissue scaffold may comprise a processed acellular tissue matrix.
- the acellular tissue matrix may be derived from human skin or from a xenogenic source.
- other tissues such as blood vessels, heart valves, fascia, nerve, connective tissue, or other collagen-containing organs or tissues may be used to create a specific acellular matrix within the scope of the present disclosure.
- the acellular tissue matrix is an acellular dermal matrix.
- acellular tissue matrices can be produced using a variety of different tissue processing techniques. For example, certain exemplary tissue processing techniques for producing acellular tissue matrices are described in U.S. Pat. Nos. 5,336,616 and 5,364,756, both to Livesey et al., in U.S. Pat. No. 6,933,326 to Schiff et al., each of which is incorporated by reference in its entirety.
- acellular tissue matrices made from non-human animals can be treated to remove various antigens, or produced from animals genetically modified to lack certain antigens.
- FIG. 2 illustrates use of a tissue scaffold to treat a cartilage defect, according to certain embodiments.
- a scaffold 180 is used to treat a cartilage defect in a long bone (e.g., femur or humerus).
- a scaffold 180 can be used to treat an articular surface or cartilage 510 of any joint.
- the tissue scaffold 180 is placed in a defect or excised area of an articular surface or cartilage 510 , and a negative pressure is applied to the tissue scaffold 180 through a fluid conduit 125 , as described above.
- a second material 190 is applied over the tissue scaffold 180 , and the second material 190 acts as a manifold to distribute pressure to tissue scaffold 180 .
- the fluid conduit is in fluid communication with the tissue scaffold 180 without a second material 180 .
- the tissue scaffold can be used as a primary treatment method or in connection with another procedure or treatment.
- cartilage repair or regeneration can be performed using a technique known in the art as microfracture. As shown in FIG. 2 , during a microfracture procedure, a surgeon creates small fractures or openings 515 in bone adjacent to an articular defect. In various instances, the fractures or openings 515 can allow chondrocytes or other cells that can differentiate into chondrocytes to migrate to the articular defect from adjacent bone, bone marrow space, or cartilage. In various instances, these cells can, in turn, help repair or regenerate cartilage.
- the tissue scaffold 180 is placed over the microfracture site, and negative pressure is applied to the scaffold.
- the tissue scaffold acts as a manifold to distribute negative pressure over the site to be treated.
- the tissue scaffold provides a substrate to support tissue growth, repair, and/or regeneration.
- negative pressure is applied to draw cells, growth factors, and/or other biologic elements into the tissue scaffold 180 from the bone 500 .
- a method of processing an acellular tissue matrix to produce a tissue scaffold is provided.
- the acellular tissue matrix comprises collagen, elastin, and vascular channels.
- the acellular tissue matrix is ALLODERM®.
- the acellular tissue matrix is STRATTICETM.
- the acellular tissue matrix added to the first aqueous sodium acetate solution is in dehydrated form.
- the acellular tissue matrix is cut into small pieces, e.g., cubes, after removal from the first aqueous sodium acetate solution prior to homogenization.
- the incubating step takes place at about 4° C. for more than 12 hours.
- the acellular tissue matrix comprises collagen, elastin, and vascular channels. In some embodiments, the acellular tissue matrix is ALLODERM®. In some embodiments, the acellular tissue matrix comprises collagen, elastin, and vascular channels. In some embodiments, the acellular tissue matrix is STRATTICETM.
- the tissue scaffold has a desired permeability.
- the permeability may be selected to allow adequate manifolding or distribution of pressure or flow applied to a wound or therapy site across the site.
- the permeability is controlled by controlling the porosity of the tissue scaffold.
- the permeability is at least 1 ⁇ 10 11 m 2 .
- sodium bicarbonate is further added to either one or both of the first or second aqueous sodium acetate solutions, and/or to the slurry.
- sodium bicarbonate can be added to the solution just before or during casting.
- the amount of sodium acetate can be selected to cause foaming of the solution and/or slurry.
- the amount of foaming is selected to control the porosity of all or a portion of a tissue scaffold.
- the slurry is frozen soon after adding sodium acetate to create a desired porosity in the tissue scaffold.
- the tissue scaffold can have a porosity that varies across its thickness.
- tissue scaffolds it may be desirable for tissue scaffolds to be resorbed by the body rather than persist for extended periods.
- tissue scaffolds persist for extended periods, e.g., several months or longer.
- extended periods provide continued tissue regrowth, remodeling, and regeneration.
- a material placed over a wound bed is generally replaced periodically (e.g., every few days).
- replacement of the materials can be painful or damaging to the wound site, especially if granulation tissue has grown into the material.
- the tissue scaffolds are bioresorbable.
- the tissue scaffolds can be placed in a wound site or implanted, and will be resorbed by the body such that the devices are not removed or replaced.
- ALLODERM® Aseptically prepared ALLODERM® is cut into strips (approximately 2-3 mm wide) and weighed dry. The desired weight is immersed in the appropriate volume of 20 mM sodium acetate to achieve a final concentration of about 0.1% to about 15.0% w/v (weight of dried material to volume of solution). The strips are then removed from solution, diced into small cubes (approximately 2 ⁇ 2 mm) using a scalpel, and immersed in a second 20 mM aqueous sodium acetate solution to achieve the desired % w/v. The suspension is then homogenized at full speed using a Dremmel type probe tip for 1 minute, followed by cooling on ice for about 1 minute or longer.
- freezing rate, freezing temperature, the addition of sodium bicarbonate and the material compositions may all be modified.
- the modifications control the final composition, mechanical strength, hydration, and/or fluid conductance of the resulting tissue scaffold.
- ALLODERM® Aseptically prepared ALLODERM® was cut into strips (approximately 2-3 mm wide) and weighed dry. The strips were immersed in the appropriate volume of 20 mM sodium acetate to achieve a final concentration of 5.0% w/v (weight of dried material to volume of solution) and pH of about 3.4. The samples were incubated overnight at 4° C. After incubation overnight, the sample pH rose to about 7.0, and the pH was adjusted back to about 3.4 before further processing. Samples were homogenized three times using a Dremmel type probe to produce a slurry. Samples were cooled on ice for 1 minute between each homogenization step. The samples were casted in six-well culture plates.
- FIGS. 3A-3D are graphs showing the strut spacing for the tissue scaffolds.
- FIG. 3A represents data for a 1 ml sample
- FIG. 3B is date for a 2 ml sample
- FIG. 3C is data for a 4 ml sample
- FIG. 3D is data for a 6 ml sample.
- the ability of tissue scaffolds to bind water can be important for scaffolds remaining hydrated and being effective in supporting tissue repair or regeneration.
- Sample permeability and water-binding capacity were studied as a function of sample composition (i.e., variation in w/v %). Scaffolds were produced by casting and lyophilizing slurries having varying compositions.
- Aseptically prepared ALLODERM® was cut into strips (approximately 2-3 mm wide) and weighed dry. The desired weight of the strips was immersed in the appropriate volume of 20 mM sodium acetate to achieve a final concentrations of 0.1% w/v, 0.5% w/v, 1.0% w/v, 3.0% w/v, 5% w/v, and 8% w/v (each being material weight to sodium acetate solution volume). Each sample pH was about 3.4. Samples were incubated overnight at 4° C. After incubation, the sample pHs rose to about 7.0, and the pHs were adjusted back to about 3.4 before further processing. Samples were homogenized three times using a Dremmel type probe to produce a slurry. Samples were cooled on ice for 1 minute between each homogenization step. Samples were cooled at ⁇ 70° C. for four hours and were then freeze-dried to produce tissue scaffolds.
- Table 2 provides data for sample water-binding capacity as a function of sample composition
- FIG. 4 is a graph showing the permeability versus composition for tissue scaffolds. As shown in Table 2 and FIG. 4 , as the sample w/v % increased, the sample water-binding capacity increased and sample permeability decreased.
- Table 3 provides data on sample strut density and porosity as a function of sample composition.
- the sample porosity followed a relatively normal distribution, with sample strut spacing and porosity increasing as sample composition varies from 0.1% to about 5.0%, and decreasing with further increase in sample composition.
- Foam Strut Spacing for Samples Cooled at ⁇ 200° C.
- Foam Strut Spacing (microns) Average 9.5 Standard Deviation 2.2 Median 9.7 Maximum 14.2 Minimum 4.2
- FIGS. 6A-6B are photomicrographs of chondrocytes cultured on tissue scaffolds produced with ALLODERM®
- FIGS. 7A-7B are photomicrographs of chondrocytes cultured on tissue scaffolds produced with STRATTICETM. Both human and porcine tissue scaffolds supported chondrocyte growth and infiltration, and grossly appeared to maintain chondrocyte phenotypes.
- tissue growth and healing While systems and methods have been described with reference to tissue growth and healing in human patients, it should be recognized that these systems and methods for applying reduced pressure tissue treatment can be used in any living organism in which it is desired to promote tissue growth or healing. Similarly, the systems and methods may be applied to any tissue, including without limitation bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. While the healing of soft tissue may be an exemplary focus of applying reduced pressure tissue treatment as described herein, the application of reduced pressure tissue treatment, especially to tissues located beneath a patient's skin, may also be used to generate tissue growth in tissues that are not diseased, defective, or damaged.
- the percutaneous implantation techniques may be used to apply reduced pressure tissue treatment to grow additional tissue at a tissue site that can then be harvested.
- the harvested tissue may be transplanted to another tissue site to replace diseased or damaged tissue, or alternatively the harvested tissue may be transplanted to another patient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 12/540,489, filed Aug. 13, 2009, which claims priority under 35 U.S.C. § 119 to U.S. Provisional Patent Application No. 61/189,097, which was filed on Aug. 14, 2008, both of which are herein incorporated by reference.
- Reduced pressure, or vacuum-assisted, therapies can be effective for improving wound healing due to a variety of different causes and at a number of different anatomical locations. Typically, reduced pressure therapies include a porous material that is placed at a wound site, which aids in the distribution of the reduced pressure. Typical porous materials are sized to fit the wound, and may be periodically replaced with smaller pieces of the porous material as the wound begins to heal and becomes smaller. Typically, a membrane or drape is placed over the porous material to provide an airtight seal at the wound area, and a negative pressure is applied to the porous material to provide a reduced pressure at the wound site.
- According to certain embodiments, a method of processing an acellular tissue matrix for preparing a tissue scaffold is provided. In certain embodiments, a method of preparing a tissue scaffold is provided, comprising adding an acellular tissue matrix to a first aqueous solution of sodium acetate; incubating the first aqueous sodium acetate solution containing the acellular tissue matrix; removing the incubated acellular tissue matrix from the first aqueous sodium acetate solution; treating the incubated acellular tissue matrix with a second aqueous solution of sodium acetate to form a suspension; homogenizing the suspension to form a slurry; cooling the slurry; casting the slurry in a casting container; and lyophilizing the slurry. In certain embodiments, a tissue scaffold comprising an acellular tissue matrix and sodium acetate is provided. In certain embodiments, a wound treatment device comprising a reduced pressure source and a tissue scaffold is provided. In certain embodiments, a tissue scaffold, comprising an acellular tissue matrix that has been processed to have a porosity of between 75% and 90% is provided.
-
FIG. 1 illustrates a wound treatment device, which provides reduced pressure therapy, according to certain exemplary embodiments. -
FIG. 2 illustrates a method of treating a cartilage defect using a tissue scaffold, according to certain embodiments. -
FIGS. 3A-3D are graphs showing the strut spacing for tissue scaffolds, as described in Example 1. -
FIG. 4 is a graph showing the permeability versus composition for tissue scaffolds, as described in Example 2. -
FIG. 5 is a graph showing the strut spacing for a tissue scaffold produced according to certain exemplary embodiments, as described in Example 3. -
FIGS. 6A-6B are photomicrographs of chondrocytes cultured on tissue scaffolds, as described in Example 4. -
FIGS. 7A-7B are photomicrographs of chondrocytes cultured on tissue scaffolds, as described in Example 4 - Reference will now be made in detail to the certain exemplary embodiments according to the present disclosure, certain examples of which are illustrated in the accompanying drawing.
- The present disclosure pertains to a method of processing an acelluar tissue matrix for preparing a tissue scaffold. In some embodiments, the tissue scaffold of the present disclosure may be used as part of a wound treatment device that provides reduced pressure therapy. In some embodiments, the physical properties of certain tissue scaffolds such as porosity, strut density, and permeability, may be controlled or altered by adjusting the concentrations, components, and temperatures at which the scaffolds are produced.
- In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise. Also the use of the term “portion” may include part of a moiety or the entire moiety.
- The term “acellular tissue matrix,” as used herein, refers generally to any tissue matrix that is substantially free of cells and other antigenic material. In various embodiments, acellular tissue matrices derived from human or xenogenic sources may be used to produce the scaffolds. Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, nerve, or other collagen containing-organ or tissue may be used to create an acellular matrices to produce tissues scaffolds within the scope of the present disclosure.
- In certain embodiments, the term “permeability” refers generally to the movement of fluid through a porous medium. In certain embodiments, the specific permeability values of particular tissue scaffolds are calculated by Darcy's Law:
-
- where Q equals the total discharge (units of volume per time, e.g., m2/s), (A) is the cross-sectional area to flow, AP is the pressure drop across the system, p is the dynamic viscosity (in SI units e.g. kg/(m s) or Pa's), and (l) is the length over which the pressure drop is taking place over.
- The term “reduced pressure,” as used herein, generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure of tissue at the tissue site. Reduced pressure may initially generate fluid flow in the area of the tissue site and/or a fluid conduit in communication with the tissue site, for example, as shown in
FIG. 1 . As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. In some embodiments, small amounts of gas can be introduced at intervals to facilitate fluid movement if required. Unless otherwise indicated, values of pressure stated herein are gage pressures. - The term “fluid” as used herein generally refers to a gas or liquid, but may also include any other flowable material, including but not limited to gels, colloids, and foams.
- The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.
- In various embodiments, devices of the present disclosure can be used for treatment at numerous different anatomical sites. According to various embodiments, tissue scaffolds can be used in a wide array of applications. Certain exemplary applications include, but are not limited to, absorptive dressing, dermal regeneration (for example, for treatments of all types of ulcers and burns), nerve regeneration, cartilage regeneration, connective tissue regeneration or repair (for example, tendon/ligament sleeve), bone regeneration, periodontal applications, wound/foam lining, integrated bandage dressing, substrate/base for skin grafts, vascular regeneration, cosmetic surgery, cosmetic injectable gel, metal and/or polymer implant coating (for example, to increase implant integration and biocompatibility), and replacement of lost tissue (e.g., after trauma, breast reduction, mastectomy, lumpectomy, parotidectomy, or excision of tumors).
-
FIG. 1 illustrates awound treatment device 100, including a reducedpressure source 120, according to certain exemplary embodiments. In various embodiments, a variety of reduced pressure therapy devices can be used. For example, suitable reduced pressure therapy devices include V.A.C.® therapy devices produced by Kinetic Concepts, Inc. (San Antonio, Tex.). Such reduced pressure therapy devices can include a vacuum pump that can be fluidly connected to thewound site 150, via afluid conduit 125 or other fluid connection. Such devices may also include aflexible sheet 160 to cover thewound site 150 and at least partially seal the wound to allow reduced pressure therapy to be provided at the wound site. In addition, such systems may include atissue scaffold 180, that is placed at the wound site and facilitates wound closure, healing, tissue regeneration or repair, prevents or treats infection, and/or has other beneficial effects. In certain embodiments, the tissue scaffold 180 assists in distributing fluid flow or negative pressure across a site to be treated. - In some embodiments, the
flexible sheet 160 will include a flexible polymeric material. In various embodiments, any suitable polymeric material can be selected. In various embodiments, the material does not cause significant irritation, immune response, or heightened risk of infection. In various embodiments, the specific material generally should be of sufficient thickness and impermeability to allow reduced pressure therapy at a wound site under thesheet 160. - In some embodiments, the
device 100 will include an adhesive. As used here, and throughout the disclosure, adhesive will be understood to refer to any substance that causes the surfaces of two objects to be attached to one another. In various embodiments, suitable adhesives can include a variety of different cements, glues, resins, or other materials that can facilitate attachment of theflexible sheet 160 to tissue. In some embodiments, the adhesive can include a pressure-sensitive acrylic adhesive. In various embodiments, the adhesives can be applied directly to the structures to be joined, or the adhesives may be applied on tape, or with other supporting substrate materials. - In some embodiments, the adhesive can be applied to a surface of the
flexible sheet 160 to attach the sheet to skin or other tissue. In some embodiments, the adhesive will be applied to the surface of the sheet and packaged and/or distributed with thesheet 160. In some embodiments, the adhesive is applied to a surface of thesheet 160 and covered by a non-adhesive material that can be removed to expose the adhesive for use. In certain embodiments, the adhesive can be supplied as a separate component (e.g., in a container or on a tape) that is applied to thesheet 160 to attach thesheet 160 to tissue. In some embodiments, the adhesive can be applied to a patient's skin or other tissue, and the sheet can be applied to the adhesive. - In various embodiments,
tissue scaffold 180 can include a variety of suitable materials. For example, a number of different tissue scaffolds will be compatible for use with the above-noted V.A.C.® treatment systems. In some embodiments, the tissue scaffold may comprise a processed acellular tissue matrix. In some embodiments, the acellular tissue matrix may be derived from human skin or from a xenogenic source. In various embodiments, other tissues such as blood vessels, heart valves, fascia, nerve, connective tissue, or other collagen-containing organs or tissues may be used to create a specific acellular matrix within the scope of the present disclosure. In some embodiments, the acellular tissue matrix is an acellular dermal matrix. In various embodiments, the acellular dermal matrix is produced from human dermis or pig dermis. In some embodiments, the methods disclosed herein utilize a dehydrated acellular tissue matrix tissue, such as ALLODERM®, which is commercially available from LifeCell Corporation, Branchburg, N.J. In some embodiments, the methods disclosed herein utilize an acellular tissue matrix tissue, such as STRATTICE™, which is commercially available from LifeCell Corporation, Branchburg, N.J. - In various embodiments, acellular tissue matrices can be produced using a variety of different tissue processing techniques. For example, certain exemplary tissue processing techniques for producing acellular tissue matrices are described in U.S. Pat. Nos. 5,336,616 and 5,364,756, both to Livesey et al., in U.S. Pat. No. 6,933,326 to Schiff et al., each of which is incorporated by reference in its entirety. In some embodiments, acellular tissue matrices made from non-human animals can be treated to remove various antigens, or produced from animals genetically modified to lack certain antigens. For example, certain exemplary methods of processing tissues to produce acellular matrices with reduced amounts of or lacking alpha-1,3-galactose moieties, are described in Hui, X. et al., “A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-a-(1,3)-Galactose and Retention of Matrix Structure,” Tissue Engineering, Vol. 15, 1-13 (2009), which is incorporated by reference in its entirety
-
FIG. 2 illustrates use of a tissue scaffold to treat a cartilage defect, according to certain embodiments. As shown, ascaffold 180 is used to treat a cartilage defect in a long bone (e.g., femur or humerus). In various embodiments, ascaffold 180 can be used to treat an articular surface orcartilage 510 of any joint. In various embodiments, thetissue scaffold 180 is placed in a defect or excised area of an articular surface orcartilage 510, and a negative pressure is applied to thetissue scaffold 180 through afluid conduit 125, as described above. In some embodiments, asecond material 190 is applied over thetissue scaffold 180, and thesecond material 190 acts as a manifold to distribute pressure totissue scaffold 180. In some embodiments, the fluid conduit is in fluid communication with thetissue scaffold 180 without asecond material 180. - In some embodiments, the tissue scaffold can be used as a primary treatment method or in connection with another procedure or treatment. For example, in various embodiments, cartilage repair or regeneration can be performed using a technique known in the art as microfracture. As shown in
FIG. 2 , during a microfracture procedure, a surgeon creates small fractures oropenings 515 in bone adjacent to an articular defect. In various instances, the fractures oropenings 515 can allow chondrocytes or other cells that can differentiate into chondrocytes to migrate to the articular defect from adjacent bone, bone marrow space, or cartilage. In various instances, these cells can, in turn, help repair or regenerate cartilage. - In some embodiments, after the fractures or
openings 515 are produced in thebone 500, thetissue scaffold 180 is placed over the microfracture site, and negative pressure is applied to the scaffold. In some embodiments, the tissue scaffold acts as a manifold to distribute negative pressure over the site to be treated. In some embodiments, the tissue scaffold provides a substrate to support tissue growth, repair, and/or regeneration. In some embodiments, negative pressure is applied to draw cells, growth factors, and/or other biologic elements into thetissue scaffold 180 from thebone 500. - In some embodiments, a method of processing an acellular tissue matrix to produce a tissue scaffold is provided. In some embodiments, the acellular tissue matrix comprises collagen, elastin, and vascular channels. In some embodiments, the acellular tissue matrix is ALLODERM®. In some embodiments, the acellular tissue matrix is STRATTICE™.
- In some embodiments, a method for producing a tissue scaffold is provided In some embodiments, a method comprises adding an acellular tissue matrix to a first aqueous solution of sodium acetate; incubating the first aqueous sodium acetate solution containing the acellular tissue matrix; removing the incubated acellular tissue matrix from the first aqueous sodium acetate solution; treating the incubated acellular tissue matrix with a second aqueous solution of sodium acetate to form a suspension; homogenizing the suspension to form a slurry; cooling the slurry; casting the slurry in a casting container; and lyophilizing the frozen slurry.
- In some embodiments, the acellular tissue matrix added to the first aqueous sodium acetate solution is in dehydrated form. In some embodiments, the acellular tissue matrix is cut into small pieces, e.g., cubes, after removal from the first aqueous sodium acetate solution prior to homogenization. In some embodiments, the incubating step takes place at about 4° C. for more than 12 hours.
- In some embodiments, the homogenizing step and the cooling step are repeated at least three times. In some embodiments, the homogenizing step is accomplished by a homogenizing Dremmel probe. In some embodiments, the cooling step is accomplished at about 0° C. for about 1.5 minutes or longer. In some embodiments, the casted slurry is frozen at about −70° C. or less for about 2 hours or longer. In some embodiments, the casted slurry is frozen at about −200° C. or less.
- In some embodiments, the desired shape and height of the resulting tissue scaffold is determined by the shape and height of the casting container. In some embodiments, the first aqueous sodium acetate solution has a pH of about 3.4, or between about 3.4 and 7.0, or between about 3.4 and 5.0. In some embodiments, the first aqueous solution achieves a final concentration of about 0.1% w/v to about 15% w/v of acellular tissue matrix. In some embodiments, the porosity of the resulting tissue scaffold is from about 75% to about 90%. In some embodiments, the strut density of the resulting tissue scaffold is from about 0.13 g/cm3 to about 0.24 g/cm3. In some embodiments, mechanical strength, porosity, hydration and fluid conductance are controlled by freezing rate, freezing temperature, and the composition of the casting container. In some embodiments, the acellular tissue matrix comprises collagen, elastin, and vascular channels. In some embodiments, the acellular tissue matrix is ALLODERM®. In some embodiments, the acellular tissue matrix comprises collagen, elastin, and vascular channels. In some embodiments, the acellular tissue matrix is STRATTICE™.
- In certain embodiments, the tissue scaffold has a desired permeability. For example, the permeability may be selected to allow adequate manifolding or distribution of pressure or flow applied to a wound or therapy site across the site. In certain embodiments, the permeability is controlled by controlling the porosity of the tissue scaffold. In certain embodiments, the permeability is at least 1×1011 m2.
- In some embodiments, sodium bicarbonate is further added to either one or both of the first or second aqueous sodium acetate solutions, and/or to the slurry. In some embodiments, sodium bicarbonate can be added to the solution just before or during casting. The amount of sodium acetate can be selected to cause foaming of the solution and/or slurry. In certain embodiments, the amount of foaming is selected to control the porosity of all or a portion of a tissue scaffold. In certain embodiments, the slurry is frozen soon after adding sodium acetate to create a desired porosity in the tissue scaffold. In some embodiments, the tissue scaffold can have a porosity that varies across its thickness.
- In some embodiments, the tissue scaffold comprises an acellular tissue matrix and sodium acetate. In some embodiments, the tissue scaffold further comprises sodium bicarbonate.
- In certain instances, it may be desirable for tissue scaffolds to be resorbed by the body rather than persist for extended periods. In certain instances, tissue scaffolds persist for extended periods, e.g., several months or longer. In certain instances, extended periods provide continued tissue regrowth, remodeling, and regeneration. In certain instances, with some negative pressure wound treatment systems, a material placed over a wound bed is generally replaced periodically (e.g., every few days). In certain instances, replacement of the materials can be painful or damaging to the wound site, especially if granulation tissue has grown into the material. In some embodiments, the tissue scaffolds are bioresorbable. In some embodiments, the tissue scaffolds can be placed in a wound site or implanted, and will be resorbed by the body such that the devices are not removed or replaced.
- The following examples demonstrate certain exemplary embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples herein may be modified to achieve similar results.
- Aseptically prepared ALLODERM® is cut into strips (approximately 2-3 mm wide) and weighed dry. The desired weight is immersed in the appropriate volume of 20 mM sodium acetate to achieve a final concentration of about 0.1% to about 15.0% w/v (weight of dried material to volume of solution). The strips are then removed from solution, diced into small cubes (approximately 2×2 mm) using a scalpel, and immersed in a second 20 mM aqueous sodium acetate solution to achieve the desired % w/v. The suspension is then homogenized at full speed using a Dremmel type probe tip for 1 minute, followed by cooling on ice for about 1 minute or longer. The suspension is cooled sufficiently to prevent heating of the suspension to near the melting point of collagen within the suspension during subsequent homongenization, thereby preventing thermal damage to the collagen. The homogenization and cooling steps are repeated three (3) times. The homogenizer tip is then rinsed, and the slurry is then poured into the desired casting containers for the right shape and height. The containers are then covered and placed in a freezer at −70° C. for more than 2 hours to ensure complete freezing. As described below, samples may be frozen at other temperatures to achieve faster freezing, e.g., on liquid nitrogen at about −200° C. The samples are removed from the freezer and placed in a freeze drier. The scaffolds are then removed from the freeze drier upon completion (e.g., about 24 hours or when the temperature of the vessel reaches ambient temperature) of the lyophilization process, and are stored in a dessicator or under vacuum. In some embodiments, sodium bicarbonate can be added to the sample before or after any of the homogenization steps, or just before or during casting.
- In various embodiments, freezing rate, freezing temperature, the addition of sodium bicarbonate and the material compositions may all be modified. In certain embodiments, the modifications control the final composition, mechanical strength, hydration, and/or fluid conductance of the resulting tissue scaffold.
- The effect of material thickness on scaffold structure was evaluated. Aseptically prepared ALLODERM® was cut into strips (approximately 2-3 mm wide) and weighed dry. The strips were immersed in the appropriate volume of 20 mM sodium acetate to achieve a final concentration of 5.0% w/v (weight of dried material to volume of solution) and pH of about 3.4. The samples were incubated overnight at 4° C. After incubation overnight, the sample pH rose to about 7.0, and the pH was adjusted back to about 3.4 before further processing. Samples were homogenized three times using a Dremmel type probe to produce a slurry. Samples were cooled on ice for 1 minute between each homogenization step. The samples were casted in six-well culture plates. The wells in which samples were casted had a cylindrical structure with a 35 mm diameter. Samples were cooled at −70° C. for four hours and were then freeze-dried to produce tissue scaffolds. Scaffolds were produced using slurry volumes of 1 ml, 2 ml, 4 ml, and 6 ml.
FIGS. 3A-3D are graphs showing the strut spacing for the tissue scaffolds.FIG. 3A represents data for a 1 ml sample,FIG. 3B is date for a 2 ml sample,FIG. 3C is data for a 4 ml sample, andFIG. 3D is data for a 6 ml sample. - As shown in
FIGS. 3A-3D , thicker samples resulted in a larger pore size (larger strut spacing) and wider variation pore size. Table 1 provides data including the average pore size, standard deviation, median pore size, and minimum and maximum pore sizes for samples having varying thicknesses. As shown in Table 1, the standard deviation of pore size, range of pore sizes (difference between minimum and maximum pore sizes) and average pore size all increase with increasing material thickness. -
TABLE 1 Final Volume of NaOAc for Scaffolds Produced with 5% w/v Slurry (material to casting solution) 1 ml 2 ml 4 ml 6 ml Average Strut 89 μm 108 μm 133 μm 212 μm Spacing Standard 29 μm 41 μm 51 μm 67 μm Deviation of Strut Spacing Median Strut 83 μm 101 μm 97 μm 202 μm Spacing Maximum Strut 167 μm 211 μm 260 μm 356 μm Spacing Minimum Strut 43 μm 33 μm 35 μm 96 μm Spacing - In certain embodiments, the ability of tissue scaffolds to bind water can be important for scaffolds remaining hydrated and being effective in supporting tissue repair or regeneration. Sample permeability and water-binding capacity were studied as a function of sample composition (i.e., variation in w/v %). Scaffolds were produced by casting and lyophilizing slurries having varying compositions.
- Aseptically prepared ALLODERM® was cut into strips (approximately 2-3 mm wide) and weighed dry. The desired weight of the strips was immersed in the appropriate volume of 20 mM sodium acetate to achieve a final concentrations of 0.1% w/v, 0.5% w/v, 1.0% w/v, 3.0% w/v, 5% w/v, and 8% w/v (each being material weight to sodium acetate solution volume). Each sample pH was about 3.4. Samples were incubated overnight at 4° C. After incubation, the sample pHs rose to about 7.0, and the pHs were adjusted back to about 3.4 before further processing. Samples were homogenized three times using a Dremmel type probe to produce a slurry. Samples were cooled on ice for 1 minute between each homogenization step. Samples were cooled at −70° C. for four hours and were then freeze-dried to produce tissue scaffolds.
- Table 2 provides data for sample water-binding capacity as a function of sample composition, and
FIG. 4 is a graph showing the permeability versus composition for tissue scaffolds. As shown in Table 2 andFIG. 4 , as the sample w/v % increased, the sample water-binding capacity increased and sample permeability decreased. -
TABLE 2 Soaking Capacity of Exemplary Tissue Scaffolds Dry AlloDerm/ Soaking Thickness Length Breadth Volume NaOac Capcity (% (% (% (% (w/v) (g/cm3) change) change) change) change) 0.1% n/a −79.2 8.5 5.6 −76.1 0.5% 0.53 −42.9 1.5 1.6 −41.0 1.0% 0.32 3.8 2.3 3.4 9.8 3.0% 0.56 3.6 2.4 2.6 8.8 5.0% 0.68 7.6 6.7 4.8 20.3 8.0% 0.80 9.1 0.7 0.8 10.8 - Table 3 provides data on sample strut density and porosity as a function of sample composition. The sample porosity followed a relatively normal distribution, with sample strut spacing and porosity increasing as sample composition varies from 0.1% to about 5.0%, and decreasing with further increase in sample composition.
-
TABLE 3 Porosity and Strut Density of Tissue Scaffolds Dry AlloDerm/NaOAc (w/v) Strut Density (g/cm3) % Porosity 0.1% 0.132 89.0 0.5% 0.075 84.6 1.0% 0.154 89.9 4.0% 0.264 88.7 5.0% 0.423 91.0 8.0% 0.486 89.2 10.0% 0.395 84.1 15.0% 0.234 79.7 -
-
TABLE 4 Foam Strut Spacing for Samples Cooled at −200° C. Foam Strut Spacing (microns) Average 9.5 Standard Deviation 2.2 Median 9.7 Maximum 14.2 Minimum 4.2 -
FIGS. 6A-6B are photomicrographs of chondrocytes cultured on tissue scaffolds produced with ALLODERM®, andFIGS. 7A-7B are photomicrographs of chondrocytes cultured on tissue scaffolds produced with STRATTICE™. Both human and porcine tissue scaffolds supported chondrocyte growth and infiltration, and grossly appeared to maintain chondrocyte phenotypes. - While systems and methods have been described with reference to tissue growth and healing in human patients, it should be recognized that these systems and methods for applying reduced pressure tissue treatment can be used in any living organism in which it is desired to promote tissue growth or healing. Similarly, the systems and methods may be applied to any tissue, including without limitation bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. While the healing of soft tissue may be an exemplary focus of applying reduced pressure tissue treatment as described herein, the application of reduced pressure tissue treatment, especially to tissues located beneath a patient's skin, may also be used to generate tissue growth in tissues that are not diseased, defective, or damaged. For example, it may be desired to use the percutaneous implantation techniques to apply reduced pressure tissue treatment to grow additional tissue at a tissue site that can then be harvested. The harvested tissue may be transplanted to another tissue site to replace diseased or damaged tissue, or alternatively the harvested tissue may be transplanted to another patient.
- Other embodiments will be apparent to those skilled in the art from consideration of the specification and practice of the devices and methods disclosed herein.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/544,433 US20190365950A1 (en) | 2008-08-14 | 2019-08-19 | Tissue scaffolds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18909708P | 2008-08-14 | 2008-08-14 | |
US12/540,489 US10413636B2 (en) | 2008-08-14 | 2009-08-13 | Tissue scaffolds |
US16/544,433 US20190365950A1 (en) | 2008-08-14 | 2019-08-19 | Tissue scaffolds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/540,489 Continuation US10413636B2 (en) | 2008-08-14 | 2009-08-13 | Tissue scaffolds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190365950A1 true US20190365950A1 (en) | 2019-12-05 |
Family
ID=41527785
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/540,489 Expired - Fee Related US10413636B2 (en) | 2008-08-14 | 2009-08-13 | Tissue scaffolds |
US16/544,433 Abandoned US20190365950A1 (en) | 2008-08-14 | 2019-08-19 | Tissue scaffolds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/540,489 Expired - Fee Related US10413636B2 (en) | 2008-08-14 | 2009-08-13 | Tissue scaffolds |
Country Status (6)
Country | Link |
---|---|
US (2) | US10413636B2 (en) |
EP (4) | EP3202429A1 (en) |
AU (1) | AU2009281937B2 (en) |
CA (1) | CA2731082C (en) |
TW (1) | TWI432230B (en) |
WO (1) | WO2010019753A2 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8469779B1 (en) | 2009-01-02 | 2013-06-25 | Lifecell Corporation | Method for debristling animal skin |
US9649408B1 (en) | 2009-11-05 | 2017-05-16 | Lifecell Corporation | Systems and methods for sterilization of bone or bone components |
JP5930476B2 (en) * | 2010-03-25 | 2016-06-08 | ライフセル コーポレーションLifeCell Corporation | Production of regenerative tissue scaffolds |
WO2012122044A2 (en) | 2011-03-04 | 2012-09-13 | Orthovita, Inc. | Flowable collagen-based hemostat and methods of use |
CA2832838C (en) | 2011-04-14 | 2019-08-13 | Lifecell Corporation | Regenerative tissue matrix flakes |
BR112013030492B1 (en) | 2011-05-31 | 2020-03-17 | Lifecell Corporation | METHOD TO PRODUCE A FABRIC PRODUCT, FABRIC PRODUCT PRODUCED BY A PROCESS |
US9089523B2 (en) | 2011-07-28 | 2015-07-28 | Lifecell Corporation | Natural tissue scaffolds as tissue fillers |
WO2013070881A1 (en) * | 2011-11-10 | 2013-05-16 | Lifecell Corporation | Method for elimination of space through tissue approximation |
US9532863B2 (en) | 2011-12-20 | 2017-01-03 | Lifecell Corporation | Sheet tissue products |
BR112014014975B1 (en) | 2011-12-20 | 2019-06-25 | Lifecell Corporation | A method of producing a fabric composition |
WO2013112350A1 (en) | 2012-01-24 | 2013-08-01 | Lifecell Corporation | Elongated tissue matrices |
EP2822610B1 (en) | 2012-03-08 | 2018-12-26 | LifeCell Corporation | Enzyme-activated collagen and tissue matrices |
CA2871665A1 (en) | 2012-04-24 | 2013-10-31 | Lifecell Corporation | Flowable tissue matrices |
ES2749178T3 (en) | 2012-04-24 | 2020-03-19 | Lifecell Corp | Functionalized tissue matrices |
WO2014008184A1 (en) | 2012-07-05 | 2014-01-09 | Lifecell Corporation | Tissue-based drain manifolds |
WO2014011402A1 (en) | 2012-07-13 | 2014-01-16 | Lifecell Corporation | Methods for improved treatment of adipose tissue |
EP3332816B1 (en) | 2012-09-26 | 2020-11-04 | LifeCell Corporation | Processed adipose tissue |
AU2014215646B2 (en) | 2013-02-06 | 2017-10-19 | Lifecell Corporation | Methods for localized modification of tissue products |
US20150037436A1 (en) | 2013-07-30 | 2015-02-05 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
WO2016130559A1 (en) | 2015-02-10 | 2016-08-18 | Lifenet Health | Biologically functional soft tissue scaffolds and implants |
CN104740685A (en) * | 2015-04-16 | 2015-07-01 | 烟台隽秀生物科技有限公司 | Nerve repairing film and preparation method thereof |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
WO2017044682A1 (en) * | 2015-09-11 | 2017-03-16 | Lifecell Corporation | Perforated tissue matrix |
AU2016367116A1 (en) | 2015-12-11 | 2018-06-14 | Lifecell Corporation | Wound treatment device |
CN106913908B (en) * | 2015-12-25 | 2020-05-26 | 北京瑞健高科生物科技有限公司 | Cell growth support with structure memory characteristic |
CN106913907B (en) * | 2015-12-25 | 2022-04-05 | 北京瑞健高科生物科技有限公司 | Preparation method of cell growth scaffold with structural memory characteristic |
USD856517S1 (en) | 2016-06-03 | 2019-08-13 | Musculoskeletal Transplant Foundation | Asymmetric tissue graft |
US10945831B2 (en) | 2016-06-03 | 2021-03-16 | Musculoskeletal Transplant Foundation | Asymmetric tissue graft |
AU2017274190A1 (en) | 2016-06-03 | 2018-12-13 | Lifecell Corporation | Methods for localized modification of tissue products |
US20170368230A1 (en) * | 2016-06-23 | 2017-12-28 | Dermagenesis, Llc | Matrix construction |
AU2017292652B2 (en) | 2016-07-05 | 2022-03-24 | Lifecell Corporation | Tissue matrices incorporating multiple tissue types |
TWI584829B (en) | 2016-08-23 | 2017-06-01 | 國立成功大學 | Moulding container for tissue engineering scaffolds |
US11045583B2 (en) | 2016-12-22 | 2021-06-29 | Lifecell Corporation | Devices and methods for tissue cryomilling |
US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
JP7297739B2 (en) | 2017-10-18 | 2023-06-26 | ライフセル コーポレーション | Adipose tissue products and manufacturing methods |
WO2019079672A1 (en) | 2017-10-19 | 2019-04-25 | Lifecell Corporation | Flowable acellular tissue matrix products and methods of production |
US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
US10813743B2 (en) | 2018-09-07 | 2020-10-27 | Musculoskeletal Transplant Foundation | Soft tissue repair grafts and processes for preparing and using same |
USD895812S1 (en) | 2018-09-07 | 2020-09-08 | Musculoskeletal Transplant Foundation | Soft tissue repair graft |
MX2021014654A (en) | 2019-05-30 | 2022-03-11 | Lifecell Corp | Biologic breast implant. |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562244A (en) | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
US4569348A (en) | 1980-02-22 | 1986-02-11 | Velcro Usa Inc. | Catheter tube holder strap |
US4373519A (en) | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
MX163953B (en) * | 1984-03-27 | 1992-07-03 | Univ New Jersey Med | PROCEDURE FOR PREPARING A BIODEGRADABLE COLLAGEN MATRIX |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
JP2719671B2 (en) | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | Wound dressing |
AU650045B2 (en) | 1990-09-12 | 1994-06-09 | Lifecell Corporation | Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US8067149B2 (en) | 1990-09-12 | 2011-11-29 | Lifecell Corporation | Acellular dermal matrix and method of use thereof for grafting |
US5263971A (en) | 1991-02-13 | 1993-11-23 | Life Medical Sciences, Inc. | Apparatus for the closure of wide skin defects by stretching of skin |
US5149331A (en) | 1991-05-03 | 1992-09-22 | Ariel Ferdman | Method and device for wound closure |
US5645081A (en) | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
US7198046B1 (en) | 1991-11-14 | 2007-04-03 | Wake Forest University Health Sciences | Wound treatment employing reduced pressure |
US5437651A (en) | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
US5549584A (en) | 1994-02-14 | 1996-08-27 | The Kendall Company | Apparatus for removing fluid from a wound |
US5993844A (en) * | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
US6135116A (en) | 1997-07-28 | 2000-10-24 | Kci Licensing, Inc. | Therapeutic method for treating ulcers |
GB9719520D0 (en) | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
US6071267A (en) | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
CA2332986C (en) | 1998-05-26 | 2009-09-08 | Lifecell Corporation | Cryopreservation of human red blood cells |
US6933326B1 (en) | 1998-06-19 | 2005-08-23 | Lifecell Coporation | Particulate acellular tissue matrix |
US6856821B2 (en) | 2000-05-26 | 2005-02-15 | Kci Licensing, Inc. | System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure |
US20040028738A1 (en) | 2000-10-05 | 2004-02-12 | Lynn L.H. Huang | Process for the preparation of porous collagen matrix |
IL139708A0 (en) * | 2000-11-15 | 2002-02-10 | Amiel Gilad | Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering |
TWI284665B (en) | 2001-08-17 | 2007-08-01 | Univ Nat Cheng Kung | Fabrication method of the porous collagen matrix |
AU2002362932B2 (en) | 2001-10-18 | 2008-06-19 | Lifecell Corporation | Remodeling of tissues and organs |
AUPS242702A0 (en) * | 2002-05-21 | 2002-06-13 | Colltech Australia Limited | Improved method for the extraction and purification of collagen |
US7498040B2 (en) | 2005-10-12 | 2009-03-03 | Lifenet Health | Compositions for repair of defects in osseous tissues, and methods of making the same |
US7402319B2 (en) | 2002-09-27 | 2008-07-22 | Board Of Regents, The University Of Texas System | Cell-free tissue replacement for tissue engineering |
AU2004259019B2 (en) | 2003-07-21 | 2010-09-23 | Lifecell Corporation | Acellular tissue matrices made from galactose alpha-1,3-galactose-deficient tissue |
EP1677703A4 (en) * | 2003-10-02 | 2009-09-02 | Depuy Spine Inc | Chemical treatment for removing cellular and nuclear material from naturally occurring extracellular matrix-based biomaterials |
US20060073592A1 (en) | 2004-10-06 | 2006-04-06 | Wendell Sun | Methods of storing tissue matrices |
AU2006294654B2 (en) | 2005-09-26 | 2012-05-24 | Lifecell Corporation | Dry platelet composition |
US7498041B2 (en) | 2005-10-12 | 2009-03-03 | Lifenet Health | Composition for repair of defects in osseous tissues |
US8267918B2 (en) | 2006-03-14 | 2012-09-18 | Kci Licensing, Inc. | System and method for percutaneously administering reduced pressure treatment using a flowable manifold |
US20070248575A1 (en) | 2006-04-19 | 2007-10-25 | Jerome Connor | Bone graft composition |
CN101553189A (en) | 2006-05-09 | 2009-10-07 | 生命细胞公司 | Reinforced biological tissue |
AU2009259835B2 (en) | 2008-06-20 | 2014-02-20 | Cook Biotech Incorporated | Composite extracellular matrix materials and medical products formed therefrom |
-
2009
- 2009-08-13 AU AU2009281937A patent/AU2009281937B2/en not_active Ceased
- 2009-08-13 EP EP16201265.2A patent/EP3202429A1/en not_active Withdrawn
- 2009-08-13 TW TW098127328A patent/TWI432230B/en not_active IP Right Cessation
- 2009-08-13 EP EP19214110.9A patent/EP3744357A1/en not_active Withdrawn
- 2009-08-13 WO PCT/US2009/053667 patent/WO2010019753A2/en active Application Filing
- 2009-08-13 EP EP09791466.7A patent/EP2313120B1/en active Active
- 2009-08-13 US US12/540,489 patent/US10413636B2/en not_active Expired - Fee Related
- 2009-08-13 CA CA2731082A patent/CA2731082C/en active Active
- 2009-08-13 EP EP11153969.8A patent/EP2319548B1/en active Active
-
2019
- 2019-08-19 US US16/544,433 patent/US20190365950A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201012491A (en) | 2010-04-01 |
WO2010019753A3 (en) | 2010-11-25 |
CA2731082A1 (en) | 2010-02-18 |
EP2313120B1 (en) | 2016-11-30 |
EP2319548A3 (en) | 2011-08-03 |
CA2731082C (en) | 2016-08-09 |
EP2319548A2 (en) | 2011-05-11 |
EP3202429A1 (en) | 2017-08-09 |
EP3744357A1 (en) | 2020-12-02 |
WO2010019753A2 (en) | 2010-02-18 |
US20100040687A1 (en) | 2010-02-18 |
US10413636B2 (en) | 2019-09-17 |
TWI432230B (en) | 2014-04-01 |
EP2313120A2 (en) | 2011-04-27 |
EP2319548B1 (en) | 2016-06-01 |
AU2009281937B2 (en) | 2015-05-07 |
AU2009281937A1 (en) | 2010-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190365950A1 (en) | Tissue scaffolds | |
EP1259269B1 (en) | Agent for the treatment of wounds | |
Ronfard et al. | Use of human keratinocytes cultured on fibrin glue in the treatment of burn wounds | |
Rennekampff et al. | Current concepts in the development of cultured skin replacements | |
AU732726B2 (en) | Biomaterial derived from vertebrate liver tissue | |
US5334527A (en) | Epidermal graft system | |
US4609551A (en) | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites | |
RU2447878C2 (en) | Osteogenesis and chondrogenesis activation | |
JP5224250B2 (en) | Medical substitute membrane | |
US20080260801A1 (en) | Composite material, especially for medical use, and method for producing the material | |
JPH11503946A (en) | Artificial skin containing a biocompatible substance based on a hyaluronic acid derivative as a support | |
US10149924B1 (en) | Ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof | |
Kangesu et al. | A porcine model using skin graft chambers for studies on cultured keratinocytes | |
KR20220018481A (en) | Tissue-derived porous matrix and method of making and using the same | |
JPH06503735A (en) | Wound dressing and its manufacturing method | |
CN102114272A (en) | Method for preparing quaternized chitosan and plasmid DNA compound particle loaded skin regeneration material | |
EP1005873B1 (en) | Artificial skin | |
RU2240135C1 (en) | Cell culture comprising precursor cells of osteogenesis, implant based on thereof and its applying for recovery bone integrity | |
JPH08196618A (en) | Cell invasive collagen formulation, artificial skin and their manufacture | |
Donati et al. | GG LGL G LGGLGLSS GGGGGG GGG GGGLS CLINICAL APPLICATION IN EURIN GGGGGGGL GGL GGLGGGGGGGGGG L CULTURED ONI A HYALURONIC GGG LSL GGG LS GGGGGGLGGGLS | |
AU6178599A (en) | Artificial skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KCI LICENSING, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PEDROZO, HUGO;GRIFFEY, EDWARD S.;KAUFMANN, CHRISTOPHER;SIGNING DATES FROM 20090916 TO 20091023;REEL/FRAME:050115/0933 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |